vinorelbine tartrate

P1/2, N=30, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Jan 2026

P2, N=120, Recruiting, ALX Oncology Inc.

P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026

P3, N=257, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2031

Predicted drug response suggested greater sensitivity to vinorelbine/etoposide but reduced sensitivity to paclitaxel in ADORA2B/SAPCD2-high tumors. Integrating HCRG-guided stratification with MR nominates ADORA2B and SAPCD2 as MR-supported biomarkers that are overexpressed in EC yet mark favorable prognosis, a pattern consistent with a less immunosuppressive microenvironment and distinct chemosensitivity. These genes warrant histology-stratified validation and mechanistic studies and may aid risk stratification and therapeutic decision-making.

P1/2, N=108, Not yet recruiting, Intergroupe Francophone De Cancerologie Thoracique

P3, N=364, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd

In silico drug sensitivity analysis further suggested that high-risk patients may develop poorer sensitivity to five clinical drugs, including Cisplatin, Oxaliplatin, and Vinorelbine. The six-m7G-related-lncRNA signature represents a promising prognostic tool for EGC that may facilitate personalized risk stratification and guide clinical decision-making regarding adjuvant or immunotherapeutic strategies.

These findings indicate that vinorelbine-based regimens inhibit tumor spheroid growth predominantly through cytostatic mechanisms rather than induction of apoptosis. This non-apoptotic growth-control strategy may be relevant for the management of apoptosis-resistant endometrial cancer.

We constructed and verified a four-gene ORS-based prognosis model for GBM, linking replication stress to immune evasion and drug sensitivity for the first time. Experimental validation confirmed the pro-tumorigenic role of PDCL3, offering potential biomarkers and therapeutic targets.

Comparing therapies, patients treated with carboplatin/paclitaxel+anti-PD-1/anti-PD-L1 mAb or cisplatin/vinorelbine+anti-PD-1/anti-PD-L1 mAb had highest median survival (median survival months ± SE) (49.4 months ± 9.15 and 34.9 months ± 8.61 respectively) with lowest hazard ratio (HR = 0.032; 95% confidence interval (CI) [0.003-0.310], p = 0.003 and HR = 0.048; 95% CI [0.005-0.465], p = 0.0083 respectively). Multi-organ metastasis was the most common type of metastasis (20.9%). In conclusion, the addition of mAbs such as anti-programmed cell death protein 1/programmed death-ligand 1 or epidermal growth factor receptor inhibitors or vascular endothelial growth factor inhibitors to platinum-doublet chemotherapy markedly improved the overall survival and survival rates of NSCLC patients.

Adjuvant atezolizumab with cisplatin and vinorelbine did not significantly improve DFS compared with patients with resected EGFR-mutated NSCLC. These results highlight the limited benefit of immune checkpoint inhibitors in this population and the need for predictive biomarkers to guide immunotherapy strategies for improving cure rates.